- Revenue for Q4 FY24 of INR 4,946 Million, a growth of 12% (y-o-y) and for FY24 of INR 19,121 Million, a growth of 13% (y-o-y)
- EBITDA for Q4 FY24 of INR 941 Million, a growth of 21% (y-o-y) and EBITDA for FY24 of INR 3,374 Million, a growth of 11% (y-o-y)
HealthCare Global Enterprises Limited (“HCG”), the leader in India in speciality healthcare services focused on oncology and fertility today announced its audited financial results for the quarter (“Q4”) and full year ended FY24.
Highlights for quarter ended March 31st, 2024
- Consolidated Income from Operations (“Revenue”) was INR 4,946 mn as compared to INR 4,417 mn in the corresponding quarter of the previous year, reflecting a year-on-year growth of 12%
- Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“Adjusted EBITDA”) was INR 941 mn, as compared to INR 778 mn in the corresponding quarter of the previous year, a growth of 21% year-on-year
- Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“Reported EBITDA”), was INR 920 mn, as compared to INR 763 mn in the corresponding quarter of the previous year, a growth of 21% year-on-year
- EBITDA for Established centers was INR 844 mn, a growth of 9% year-on-year
- EBITDA from Emerging centers was INR 176 mn, as compared to INR 81 mn in the corresponding quarter of the previous year, a growth of 117%
- Consolidated Profit after Taxes and Minority Interest (“PAT”) of INR 213 mn, as compared to INR 84 mn in the corresponding quarter of the previous year, growing by 154% year-on-year
INR million except earnings per share
(1) Q4 FY23 includes Revenue & EBITDA from discontinued MSR operations, adjusted Revenue growth stands at 14% &
EBITDA growth stands at 23%
(2) Adjusted EBITDA excluding ESOPs and Onetime Expense
(3) PAT after Minority Interest
Business Updates for Q4 FY24
- Overall ARPOB stood at Rs. 41,802 vs. Rs. 38,042 in Q4 FY23, a growth of 10%
- Overall AOR stood at 64.2% vs. 65.4% in Q4 FY23
- RoCE (Q4FY24 Annualized)
- RoCE for Established centers stood at 20.6% vs. 20.9% in FY23. RoCE pre-corporate allocations stands at 25.0%
- RoCE for Emerging centers stood at -2.9% vs. -4.9% in FY23. RoCE pre-corporate allocations stands at -0.8%
- RoCE (Q4FY24 Annualized)
Mr. Raj Gore, CEO HealthCare Global Enterprises Ltd., added, “We are delighted to report that our revenues grew by 12% for Q4FY24 on Y-o-Y basis. Our Adjusted EBIDTA (excl. ESOP cost) for Q4FY24 stood at Rs. 94 crs, a growth of 21% Y-o-Y, with margins standing at 19.0%, an increase of 140 bps compared to the same period last year.
Over the year, we have taken multiple steps to enhance our operations and improve our profitability. After consistently achieving organic growth for 3-4 years, we’re now poised to expedite HCG’s expansion through strategic acquisitions. In addition to our expansion efforts in Indore, we are committed to further strengthening our presence in Bangalore. We are currently in the process of establishing two hospitals with 125 beds in North Bangalore and the White field area, slated to be operational within the next 12 to 15 months. These state-of-the-art facilities will enhance our capacity to cater to the growing cancer care needs of the region.
Alongside, to enhance the patient experience and streamline access to healthcare services, we have introduced the ‘HCG CARE’ smart app suite. This innovative platform provides patients with seamless access to their medical records and treatment information with just one click. The app would also help us consistently engage with patients post-treatments, to continue monitoring adherence to treatment and follow-up to improve outcomes. Already, the app has benefited over 56,000 outpatients, with active participation from 300 consulting doctors on the digital platform. Our patient-centric vision continues to guide us in making a meaningful difference in the lives of those we serve by redefining healthcare through global innovation. We pledge to uphold our commitment to “Adding Life to Years” in the coming financial years as well.”
